3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
4
Gastro-enteropancreatic neuroendocrine tumor
4
Carcinoma, Hepatocellular
2
Carcinoid Tumor
2
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Gastrointestinal Neoplasms
1
Adenoma, Islet Cell
1
Acromegaly
1
Interventions
Sunitinib
5
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Endoscopic Ultrasound-Guided Fine Needle Aspiration
2
sapanisertib
1
napabucasin
1
lutetium Lu 177 dotatate
1
lanreotide
1
irinotecan sucrosofate
1
cabozantinib
1
aflibercept
1
abemaciclib
1
X-Rays
1
Wound Healing
1
Taxes
1
Plastic Surgery Procedures
1
Phantoms, Imaging
1
Paclitaxel
1
Oxaliplatin
1
Octreotide
1
Methods
1
Melphalan
1
Leucovorin
1
Irinotecan
1
Histocompatibility Testing
1
Gemcitabine
1
Fluorouracil
1
Everolimus
1
Cytoreduction Surgical Procedures
1
Cryotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
lanreotide
×
Gastrointestinal
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled